Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Click chemistry company Shasqi has a link to the Nobel Prize in Chemistry

By Brian Buntz | November 2, 2022

ShasqiThe Royal Swedish Academy of Sciences recently awarded the 2022 Nobel Prize in Chemistry to three individuals for the development of click chemistry and bioorthogonal chemistry. Among them was Carolyn Bertozzi, a scientific advisor to Shasqi (San Francisco). The oncology company has developed a novel platform to localize and activate cancer ‘protodrugs’ at a tumor site.

In 2020, Shasqi dosed the first patient with SQ3370, a unique therapy that uses the company’s proprietary click-activated protodrugs against cancer (CAPAC) platform. SQ3370 is intended to activate the chemotherapy drug doxorubicin.

The core of the idea for Shasqi came when Shasqi’s founder and CEO, José M. Mejía Oneto, was in a research phase of an orthopedic surgery residency program at the University of California, Davis. Having earned a chemistry Ph.D., Mejía pondered if there was a better way to deliver a drug to a target site in the body. “The thing that bothered me was that only about 1% or 2% of the total dose that is given goes to the location that you want,” Mejía said. “That’s true whether you’re talking about antibiotics, pain medications or the latest cancer drug.”

José M. Mejía Oneto

José M. Mejía Oneto

Medical school students study how efficient the liver and kidneys are at filtering medicines and how delivering too much of a drug can cause harm. “The critical component is that nothing is telling a chemical structure to go to a specific location in the body,” Mejía said.

Mejía explored click chemistry, a technology that can unite two discrete molecular pieces together like a seat belt buckle. “Can you put one of those buckles in one location of the body by leveraging some of the materials that we already use inside people’s bodies?” Mejía asked.

The company sought to find biocompatible materials that could hold the click chemistry reagents in place. “We call them ‘protodrugs’ because they’re not activated by enzymatic processes,” Mejía said. “They’re activated by click chemistry alone.”

In 2014, Mejía coauthored an article showing how an implantable biomaterial that supports in vivo click chemistry can improve the delivery of some small molecules by an order of magnitude. “When these two things come together inside the human body, it leads to a higher amount of therapies at the location you want,” he said.

Also in 2014, Mejía attended a research conference in Berlin, Germany and learned that Carolyn Bertozzi was also visiting the city to receive an honorary doctorate at the Free University of Berlin. “So I go to check out her presentation there, and I introduce myself to her,” Mejía said. The two hit it off, and Bertozzi provided support for Mejía’s research.

After proving the feasibility of the concept, Mejía decided to take a leap of faith and launch a company. “It has been an incredible opportunity to take the idea from scribbling on a piece of paper all the way to a Phase 2 trial,” he said.

Mejía got in touch with the startup incubator Y Combinator, which had recently signaled its interest in helping fund pharma startups. “I go to Y Combinator, pitch for eight minutes, and they give me $125,000 to create this company,” he recalled. Shasqi was the first therapeutics company to get funding from Y Combinator in late 2015. “That was amazing to me because I was thinking I was going to cobble funding together with grants from the NSF and the NIH, which we eventually got, but the timeline to get that money is so much longer.”

Shasqi recently presented interim Phase 1 results for SQ3370 in advanced solid tumors. “The total dose of doxorubicin [we administered to the tumor site] was 12 times the dose patients usually receive,” Mejía said. “And we were not seeing the myelosuppression and the cardiac toxicity you would expect from those doses.”

Mejía reflects that Bertozzi’s work, along with that of fellow Nobel Prize winner Barry Sharpless, was fundamental for Shasqi. “I became aware of their work when I was getting my organic chemistry Ph.D., and it seemed fascinating,” he said. Barry wrote about click chemistry in a 2001 paper describing the possibility of doing chemistry in your bathtub. Carolyn takes that idea and said, ‘Well, if we can do it in a bathtub, can we do it in a cell?’” Bertozzi later proved the viability of the idea in an animal. “And that represents the foundation for everything we do,” Mejía said.


Filed Under: Drug Discovery and Development, Oncology
Tagged With: click chemistry, Shasqi
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE